NuCana stock falls 2.75 percent after patent update

Published on 10/05/2026 at 23:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NuCana stock was last at USD 1.06 on October 5, 2026, after a 2.75 percent decline. Its lead drug now has more than 85 issued patents worldwide and a European composition patent.

NCNA, US67022C3043, Illustration mit AI erstellt.

NuCana stock (ISIN US67022C3043) was last at USD 1.06 on Nasdaq on October 5, 2026, down 2.75 percent from the previous session. The latest company catalyst is a European composition-of-matter patent for NUC-7738, announced on September 30, 2026, by GlobeNewswire.

European patent expands protection

The European Patent Office granted patent EP 3683225 covering the chemical structure of NUC-7738. According to GlobeNewswire, the new grant lifts the global NUC-7738 estate above 85 issued patents, including earlier composition-of-matter patents in the United States and China.

The patent covers NuCana's lead oncology candidate as it advances through the Phase 2 part of the NuTide:701 Phase 1/2 study. The trial evaluates NUC-7738 alone in advanced solid tumors and with pembrolizumab in patients with PD-1 inhibitor-resistant metastatic melanoma, according to GlobeNewswire.

Price remains far below yearly high

At USD 1.06, the stock stood 85.32 percent below its 52-week high of USD 7.22 and USD 0.11 above its 52-week low of USD 0.95 on October 5, 2026. The session range was USD 1.03 to USD 1.12, while volume reached 62,972 shares.

NuCana's market capitalization was USD 6.4 million on October 5, 2026. The combination of a small equity value and a late-stage development program means the European patent adds intellectual-property protection, but does not by itself establish commercial revenue.

Cash runway reaches into 2029

NuCana said its cash resources are expected to fund planned operations into 2029, a forward-looking statement tied to the development timetable for NUC-7738 and the company's wider oncology pipeline, according to GlobeNewswire. The next valuation checkpoint is therefore clinical progress and milestone delivery during the remainder of 2026, rather than the patent grant alone.

NuCana stock trades near yearly low

NuCana stock was last at USD 1.06 on Nasdaq at 4:00 p.m. ET on October 5, 2026, with a market capitalization of USD 6.4 million and volume of 62,972 shares.